Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New laser combo shows promise for rosacea redness

NCT ID NCT07250165

Symptom relief Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two lasers (KTP and Nd:YAG) to treat persistent facial redness in 15 adults with rosacea. Each person received three treatments, three weeks apart. The goal was to see if the lasers could safely reduce redness and improve quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
532 nm KTP laser and microsecond 1064 nm Nd:YAG laser
What this could lead to
If successful, this laser combination could provide a safe, non-drug option to reduce persistent facial redness in rosacea patients.
What could go wrong
This was a very small study (15 people) with no comparison group, so results may not apply to everyone. Long-term safety and effectiveness are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

15 people

The number who actually took part.

Started

Aug 2024

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants aged between 18 and 65 years, without cognitive impairments, and of any gender * Patients must meet the 2017 rosacea diagnostic criteria updated by the National Rosacea Society Expert Committee * The severity of rosacea must be scored at least 2 points on the Clinician's Erythema Assessment (CEA) scale. Exclusion Criteria: * if they had undergone any treatments that could influence the prognosis of rosacea within the preceding 8 weeks * if they had taken photosensitizing or phototoxic medications within the same period * the presence of other facial conditions that might confound the efficacy assessment * participation in any drug clinical trial as a subject within the last month * the presence of severe concurrent diseases

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rosacea are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rosacea

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rosacea

Contacts and locations

Locations

  • Second Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, None Selected, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.